Загрузка...
Trastuzumab: updated mechanisms of action and resistance in breast cancer
HER2-postitive breast cancer has the second-poorest prognosis among breast cancer subtypes. One of the most effective targeted therapies for patients with HER2-positive breast cancer is trastuzumab-based. However, primary or acquired resistance to trastuzumab has been a major obstacle in the clinica...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2012-06-01
|
| Серии: | Frontiers in Oncology |
| Предметы: | |
| Online-ссылка: | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00062/full |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|